Incyte (INCY) Competitors $68.84 +1.78 (+2.65%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INCY vs. ALNY, BIIB, UTHR, NBIX, BMRN, EXAS, EXEL, RGEN, MDGL, and HALOShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Incyte vs. Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Incyte (NASDAQ:INCY) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk. Which has more risk and volatility, INCY or ALNY? Incyte has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Does the media favor INCY or ALNY? In the previous week, Incyte had 9 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 21 mentions for Incyte and 12 mentions for Alnylam Pharmaceuticals. Incyte's average media sentiment score of 0.64 beat Alnylam Pharmaceuticals' score of 0.62 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 10 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in INCY or ALNY? 97.0% of Incyte shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 17.6% of Incyte shares are held by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is INCY or ALNY more profitable? Incyte has a net margin of 0.80% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Incyte's return on equity.Company Net Margins Return on Equity Return on Assets Incyte0.80% -0.63% -0.45% Alnylam Pharmaceuticals -15.86%N/A -8.38% Does the MarketBeat Community believe in INCY or ALNY? Incyte received 89 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.16% of users gave Alnylam Pharmaceuticals an outperform vote while only 72.71% of users gave Incyte an outperform vote. CompanyUnderperformOutperformIncyteOutperform Votes122372.71% Underperform Votes45927.29% Alnylam PharmaceuticalsOutperform Votes113476.16% Underperform Votes35523.84% Do analysts prefer INCY or ALNY? Incyte currently has a consensus target price of $76.29, indicating a potential upside of 10.83%. Alnylam Pharmaceuticals has a consensus target price of $298.09, indicating a potential upside of 21.45%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incyte 1 Sell rating(s) 11 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.35Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has stronger valuation & earnings, INCY or ALNY? Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIncyte$4.08B3.25$597.60M$0.14491.71Alnylam Pharmaceuticals$2.09B15.11-$440.24M-$2.62-93.68 SummaryIncyte beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteCommercial physical research IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.26B$4.20B$5.10B$9.07BDividend YieldN/A1.78%4.90%4.21%P/E Ratio491.7555.3491.0817.15Price / Sales3.2549.001,113.51116.81Price / Cash29.7723.6242.2637.86Price / Book2.973.144.784.78Net Income$597.60M$139.50M$119.77M$225.60M7 Day Performance0.42%-2.28%-1.87%-1.23%1 Month Performance-2.29%1.05%11.46%3.07%1 Year Performance11.59%12.00%30.53%16.48% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.7055 of 5 stars$68.84+2.7%$76.29+10.8%+13.3%$13.26B$4.08B491.752,524Analyst ForecastHigh Trading VolumeALNYAlnylam Pharmaceuticals4.4124 of 5 stars$245.31-0.1%$298.09+21.5%+37.1%$31.64B$1.83B-93.682,100Analyst UpgradeBIIBBiogen4.6302 of 5 stars$150.99+0.6%$245.32+62.5%-41.0%$22.00B$9.61B13.697,570Analyst DowngradeUTHRUnited Therapeutics4.7138 of 5 stars$370.95+2.5%$370.860.0%+59.5%$16.56B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsNBIXNeurocrine Biosciences4.8249 of 5 stars$134.40+6.1%$165.00+22.8%+12.6%$13.61B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsBMRNBioMarin Pharmaceutical4.9838 of 5 stars$65.89-0.2%$94.20+43.0%-29.1%$12.56B$2.75B39.533,401Positive NewsEXASExact Sciences4.4907 of 5 stars$60.48-1.3%$72.94+20.6%-11.7%$11.19B$2.50B-52.356,600EXELExelixis4.5106 of 5 stars$36.02+2.8%$31.47-12.6%+43.4%$10.29B$2.08B22.461,310Analyst DowngradeAnalyst RevisionRGENRepligen4.0971 of 5 stars$160.24+2.4%$190.25+18.7%-19.7%$8.98B$639.92M-422.731,783Analyst ForecastPositive NewsMDGLMadrigal Pharmaceuticals4.2396 of 5 stars$309.23+1.6%$347.33+12.3%+39.5%$6.74BN/A-12.1490Positive NewsHALOHalozyme Therapeutics4.9948 of 5 stars$48.39+0.8%$61.11+26.3%+29.1%$6.16B$947.36M15.98390Analyst ForecastPositive News Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Exelixis Competitors Repligen Competitors Madrigal Pharmaceuticals Competitors Halozyme Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INCY) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
